Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Three Governors release statement re cooperation

Governor Ned Lamont of Connecticut, Governor Gina Raimondo of Rhode Island, and Governor Charlie Baker of Massachusetts have released a joint statement regarding regional policy....

| By Kelley Gipson

SpringWorks starts trial re neurofibromas

SpringWorks reports that the first patient has been dosed in the Phase 2b ReNeu clinical trial evaluating mirdametinib (formerly PD-0325901), an oral, small molecule designed...

| By Kelley Gipson

Thetis wins NIH grant re chronic fatty liver disorder

Thetis Pharmaceuticals reports it has received a Fast-Track Small Business Innovation Research Grant from the National Institutes of Health (for development of an innovative new therapy,...

| By Kelley Gipson

Rothberg Hyperfine launches portable MRI unit

Hyperfine Research, housed in Jonathan Rothberg’s Guilford-based 4Catalyzer health technology incubator, has announced that it has developed “the world’s first portable, low-cost magnetic resonance imaging (MRI)...

| By Kelley Gipson

Elidah launches ELITONE® re women’s incontinence

Elidah has announced the launch of ELITONE®, the first and only patented medical device providing non-invasive treatment for stress urinary incontinence in women. ELITONE is the...

| By Kelley Gipson

Farmington’s Azitra lands $14M funding round

A Farmington biotech working with genetic engineering and microbiome science to develop skin disease treatments said it has raised its largest money to date. Azitra...

| By Kelley Gipson

CaroGen wins AVIDIO immunotherapy patent

CaroGen reports that the United States Patent and Trademark Office has issued CaroGen’s first composition of matter patent for its Artificial Virus (AV) for Infectious Diseases...

| By Kelley Gipson

Achillion gets breakthrough status for danicopan

Achillion reports that the FDA has granted Breakthrough Therapy designation for danicopan (ACH-4471) for treatment in combination with a C5 monoclonal antibody for patients with...

| By Kelley Gipson

UConn declares Bioscience Connecticut a success

It’s been more than nine years since state lawmakers approved borrowing more than $1 billion to build-up Connecticut’s bioscience stature. A newly issued report from...

| By Kelley Gipson

Alexion agreement targets mitochondrial disease

Alexion and Stealth BioTherapeutics Corp have agreed to co-develop and commercialize elamipretide for mitochondrial diseases. Currently being evaluated in a Phase 3 study in people...